Comprehensive Clinical Development Expands Operations, Moves to New Corporate Headquarters
Comprehensive Clinical Development
is pleased to announce the expansion of the Company with the relocation to its corporate headquarters in Miramar, Florida.
The new Miramar, Florida, facility will enable further expansion for the Company’s future growth. Comprehensive has also recently expanded its operational capacity in Tacoma, Washington, with 250 beds. This clinic not only increases capacity for clinical conduct, but broadens access to special populations including oncology and the capability to conduct radiolabeled studies.
“Relocating our corporate headquarters represents an investment in our future,” stated Comprehensive CEO
Jack McGovern
. “We are extremely pleased at the rate Comprehensive is succeeding in this difficult economy and the confidence our clients have in Comprehensive. We are committed to continuing our commitment to quality delivery of clinical development services from our new headquarters. This is another step toward extending our clinical research services, therapeutic areas and customer relationships.”
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
